BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22685038)

  • 1. Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring.
    Beswick DM; Gooding WE; Johnson JT; Branstetter BF
    Laryngoscope; 2012 Jul; 122(7):1512-7. PubMed ID: 22685038
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Kim SA; Roh JL; Kim JS; Lee JH; Lee SH; Choi SH; Nam SY; Kim SY
    Eur J Cancer; 2017 Feb; 72():62-70. PubMed ID: 28027517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (18)F-FDG PET/CT surveillance at 3-6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma.
    Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Br J Cancer; 2013 Dec; 109(12):2973-9. PubMed ID: 24149172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benefit of early PET/CT surveillance in HPV-associated head and neck squamous cell carcinoma.
    Zhang I; Branstetter BF; Beswick DM; Maxwell JH; Gooding WE; Ferris RL
    Arch Otolaryngol Head Neck Surg; 2011 Nov; 137(11):1106-11. PubMed ID: 22106234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET/CT for detecting distant metastases in patients with recurrent head and neck squamous cell carcinoma.
    Yi JS; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY; Roh JL
    J Surg Oncol; 2012 Nov; 106(6):708-12. PubMed ID: 22674652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment.
    Robin P; Abgral R; Valette G; Le Roux PY; Keromnes N; Rousset J; Potard G; Palard X; Marianowski R; Salaun PY
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):72-8. PubMed ID: 25169701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative predictive value of surveillance PET/CT in head and neck squamous cell cancer.
    McDermott M; Hughes M; Rath T; Johnson JT; Heron DE; Kubicek GJ; Kim SW; Ferris RL; Duvvuri U; Ohr JP; Branstetter BF
    AJNR Am J Neuroradiol; 2013 Aug; 34(8):1632-6. PubMed ID: 23639557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of subclinical recurrence or second primary cancer using (18) F-FDG PET/CT in patients treated curatively for head and neck squamous cell carcinoma.
    Kikuchi M; Shinohara S; Hino M; Itoh K; Tona R; Kishimoto I; Harada H; Fujiwara K; Suehiro A; Naito Y
    Head Neck; 2016 Apr; 38 Suppl 1():E511-8. PubMed ID: 25783743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine surveillance scanning in HNSCC: Lung screening CT scans have value but head and neck scans do not.
    Iovoli AJ; Platek AJ; Degraaff L; Wang C; Duncan WD; Wooten KE; Arshad H; Gupta V; Kuriakose MA; Hicks WL; Platek ME; Singh AK
    Oral Oncol; 2018 Nov; 86():273-277. PubMed ID: 30409312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
    Abgral R; Le Roux PY; Keromnes N; Rousset J; Valette G; Gouders D; Leleu C; Mollon D; Nowak E; Querellou S; Salaün PY
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1839-47. PubMed ID: 22895863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer.
    Kao J; Vu HL; Genden EM; Mocherla B; Park EE; Packer S; Som PM; Kostakoglu L
    Cancer; 2009 Oct; 115(19):4586-94. PubMed ID: 19544537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative Contrast-Enhanced CT Versus ¹⁸F-FDG PET/CT Evaluation and the Prognostic Value of Extranodal Extension for Surgical Patients with Head and Neck Squamous Cell Carcinoma.
    Lee JR; Choi YJ; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1020-7. PubMed ID: 26122372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Intensive 18F-Fludeoxyglucose-Positron Emission Tomography With Computed Tomography-Based Strategy of Follow-Up in Patients Treated for Head and Neck Squamous Cell Carcinoma Who Are Clinically Asymptomatic.
    Leclère JC; Clément C; Le Pennec R; Maheo C; Gujral DM; Schick U; Le Gal G; Marianowski R; Salaun PY; Abgral R
    JAMA Netw Open; 2023 Aug; 6(8):e2326654. PubMed ID: 37526935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography-computed tomography: a superior and one-stop shop modality for treated head and neck carcinoma compared with conventional tomography.
    Ichpujani VK; Rao SA; Chaturvedi AK; Dewan AK; Choudhary PS
    J Oral Maxillofac Surg; 2014 Nov; 72(11):2319-32. PubMed ID: 25438279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence.
    Ho AS; Tsao GJ; Chen FW; Shen T; Kaplan MJ; Colevas AD; Fischbein NJ; Quon A; Le QT; Pinto HA; Fee WE; Sunwoo JB; Sirjani D; Hara W; Yao M
    Cancer; 2013 Apr; 119(7):1349-56. PubMed ID: 23225544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT.
    Nayak JV; Walvekar RR; Andrade RS; Daamen N; Lai SY; Argiris A; Smith RP; Heron DE; Ferris RL; Johnson JT; Branstetter BF
    Laryngoscope; 2007 Dec; 117(12):2129-34. PubMed ID: 17921898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of (18) FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up.
    Sagardoy T; Fernandez P; Ghafouri A; Digue L; Haaser T; de Clermont-Galleran H; Castetbon V; de Monès E
    Head Neck; 2016 Apr; 38 Suppl 1():E1271-6. PubMed ID: 26315809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.